Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Share-based Compensation (2016 - 2025)

Rocket Pharmaceuticals (RCKT) has disclosed Share-based Compensation for 10 consecutive years, with $6.1 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 44.88% to $6.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $37.1 million through Dec 2025, down 15.62% year-over-year, with the annual reading at $37.1 million for FY2025, 15.62% down from the prior year.
  • Share-based Compensation hit $6.1 million in Q4 2025 for Rocket Pharmaceuticals, down from $9.8 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $11.3 million in Q2 2024 to a low of $6.1 million in Q4 2025.
  • Historically, Share-based Compensation has averaged $9.0 million across 5 years, with a median of $9.7 million in 2022.
  • Biggest five-year swings in Share-based Compensation: surged 99.44% in 2021 and later plummeted 44.88% in 2025.
  • Year by year, Share-based Compensation stood at $7.0 million in 2021, then soared by 37.74% to $9.7 million in 2022, then increased by 2.45% to $9.9 million in 2023, then increased by 11.66% to $11.1 million in 2024, then plummeted by 44.88% to $6.1 million in 2025.
  • Business Quant data shows Share-based Compensation for RCKT at $6.1 million in Q4 2025, $9.8 million in Q3 2025, and $10.9 million in Q2 2025.